Proteomics, Genomics & Microarrays
Effi cient Transduction of CAR into T-cells
AMSBIO introduces a new selection of high-titre Chimeric Antigen Receptor (CAR) lentivirus. This cutting-edge range is specifically designed to deliver exceptional transduction efficiency, enabling efficient and successful incorporation of CAR into both resting and actively dividing T-cells.
The FDA’s 2017 approval of CAR-T cells for leukaemia and lymphoma marked a significant milestone in personalised cancer treatment. Since then, the field has experienced rapid expansion, with a surge of research focused on exploring the therapeutic potential of CAR-T cells.
Harnessing the power of CAR-T cell therapies, researchers are increasingly utilising them as a strategic approach to redirect a patient’s T-cells, enabling the targeted destruction of specific tumour cells. Among various methods, researchers have discovered that viral vectors exhibit the highest efficacy in transducing CAR into T cells, making them a preferred choice during the CAR-T cell manufacturing process.
AMSBIO’s new range of clinical-grade CAR lentivirus presents an ideal solution for ex-vivo generation of CAR-T cells. These lentiviral vectors possess the unique capability to stably integrate large DNA inserts and efficiently transduce both dividing and non-dividing cells. With AMSBIO’s CAR lentivirus, researchers gain a powerful tool to facilitate the production of CAR-T cells with enhanced stability and transduction efficiency.
AMSBIO introduces a diverse range of CAR lentivirus products meticulously tailored to accommodate various research applications. Immunotherapy researchers aiming to expedite their timelines can rely on AMSBIO’s ready-to-transduce CAR lentivirus, boasting an impressive concentration of up to 10e9 infectious units per millilitre (IFU/ml). With this high-quality resource at their disposal, researchers can efficiently maximise their experimental efficiency and advance their studies in the field of immunotherapy.
More information online:
ilmt.co/PL/nqGJ 60435pr@reply-direct.com
Seamless Pipetting for Molecular Biology
Researchers at the Immune Sensing and Signaling Dynamics group/ImmunoHUB, located at i3S in Porto, Portugal, are benefiting from the cutting-edge capabilities of Integra Biosciences’ PIPETBOY acu 2 pipette controller. This advanced tool is playing a pivotal role in their investigations into the aryl hydrocarbon receptor (AHR)’s involvement in infection and cancer. Sérgio Marinho, a research technician, explained: “The AHR is used by cells to monitor their microenvironment, providing molecular cues to identify changes in microbial communities or tumour status, as well as allowing the host to react to potential imbalances in homeostasis. As therapeutic drugs are also recognised by this mechanism, AHR modulation could impact the success of therapies too. We’re investigating this modulation at a fundamental level, to try and understand the effects of infection, particularly where multidrug-resistant bacteria are an issue, and to study why some cancer patients relapse following seemingly successful chemotherapy treatments.”
Sérgio continued: “Cell and molecular biology techniques involve a lot of liquid handling. We also perform viral transductions, which require numerous cell handling steps. The PIPETBOY acu 2 pipette controller is ideal for our serological pipetting needs; it is ergonomic, very lightweight, reliable and robust, and compatible with the various serological pipettes that we use in the lab. It also has a long battery life, which is essential when we spend many hours pipetting each day. We use them every day and are very happy with their performance. We also have a VACUSAFE aspiration system from Integra, which is ideal for cell culture assays in microplates. The eight channel tip adapter allows us to aspirate eight wells simultaneously, making the process much less laborious and saving a lot of time. It’s a real asset to our laboratory.”
More information online:
ilmt.co/PL/2XmD 60474pr@reply-direct.com
Ion Exchange HPLC Columns for Protein Charge Variant and AAV Separation Analysis
Thermo Fisher Scientific has introduced a new series of ion exchange columns that offer enhanced reproducibility, sensitivity, and durability to biopharmaceutical research labs. These columns are designed for charge-based analysis of therapeutic proteins and for separating full and empty adeno-associated virus (AAV) capsids utilised in gene therapy.
The ProPac 3R HPLC column portfolio from Thermo Scientific utilises advanced monodisperse particle technology to provide exceptional reproducibility and consistent outcomes over the lifecycle of a drug - from R&D to commercialisation. With a new 3 µm particle size, it offers superior separation capabilities, including ultra-high resolution of charge variants, faster run times, and improved peak resolution.
The collection includes robust strong anion-exchange (SAX) and strong cation-exchange (SCX) column chemistries, available in two column lengths (50mm and 100mm) and two inner diameters (2mm and 4mm).
The new line of ion exchange columns from Thermo Fisher Scientific is built to be compatible with the mobile phases and organic solvents utilised in biopharmaceutical applications. These columns are made from bio-inert materials to reduce secondary interactions. Furthermore, they offer an improved peak-to-valley resolution of charge variants to increase certainty when quantifying critical quality attributes. The columns also provide confidence in detecting and identifying new acidic or basic variants during late-stage development. They have a high sample- loading capacity and analytical flexibility that allows for excellent sensitivity and performance under a broad range of pH, temperature, and mobile phase compositions, as well as MS capabilities.
More information online:
ilmt.co/PL/OV3q 60114pr@reply-direct.com
The Spotlight could be on you! Check out our Media Information Pack for further details and send your Press Releases to
pr@intlabmate.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
